Product Datasheet

MAP3K8 Antibody

Catalog No: #33235

Package Size: #33235-1 50ul #33235-2 100ul

Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	MAP3K8 Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Applications	WB IHC
Species Reactivity	Hu
Specificity	The antibody detects endogenous levels of total MAP3K8 protein.
Immunogen Type	Peptide
Immunogen Description	Synthesized non-phosphopeptide derived from human MAP3K8 around the phosphorylation site of serine 400 (C-Q-S(p)-L-D).
Target Name	MAP3K8
Other Names	C-COT; cancer Osaka thyroid oncogene; COT proto-oncogene serine/threonine-protein kinase; EC 2.7.11.25; kinase Cot
Accession No.	Swiss-Prot: P41279NCBI Gene ID: 1326
SDS-PAGE MW	60kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C

Application Details

Western blotting: 1:500~1:3000

Immunohistochemistry: 1:50~1:100

Images



Western blot analysis of extracts from COLO cells, treated with Insulin (0.01U/ml, 15mins), using MAP3K8 (Ab-400) antibody #33235.



Immunohistochemistry analysis of paraffin-embedded human brain tissue using MAP3K8 (Ab-400) antibody #33235.

Background

Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.

Miyoshi J.,Mol. Cell. Biol. 11:4088-4096(1991).
Aoki M., J. Biol. Chem. 268:22723-22732(1993).
Chan A.M.,Oncogene 8:1329-1333(1993).

Published Papers

el at., Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.In J Exp Clin Cancer Res. On 2018 Nov 27 by Qiang Z, Zhou ZY et al..PMID: 30482227, , (2018)

PMID:30482227

el at., Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology. In Elife on 2021 Dec 7 by Timothy M Errington, Alexandria Denis,

et al..PMID:34874009, , (2021)

PMID:34874009

Note: This product is for in vitro research use only and is not intended for use in humans or animals.